Phase II Clinical Trial of Intraoral Grafting of Human Tissue Engineered Oral Mucosa

Phase 2

Terminated

Interventions: Biological: POM (Palatal oral mucosa)
Biological: EVPOME (autogenous ex vivo produced oral mucosa equivalent)

Brief Summary: The purpose of this study is to improve the current standard of care of repairing mouth soft tissue defects.

Detailed Description: This study will test a tissue equivalent ex vivo produced oral mucosa equivalent(EVPOME), which is a subject's own cells grown on top of a piece of AlloDerm (a commercially available freeze dried human cadaver tissue that is routinely used in present day surgical reconstructive procedures) to create a new piece of soft tissue for use only in that subject's body. The tissue equivalent product will be tested against a non-experimental method of grafts, the gold standard a piece of palatal oral mucosa (POM) to see which works best. Each subject will be randomly assigned to receive either the EVPOME or POM to cover the defect in their mouth. The objective of the study is to assess the safety and efficacy for the use of human EVPOME for soft tissue intraoral grafting procedures compared to the "gold standard" palatal oral mucosa (POM) graft.

Recruitment & Eligibility

Inclusion Criteria

Deficient band (<3mm) of keratinized mucosa prior to or following dental implant placement
Surgery to increase width of keratinized mucosa is clinically indicated or requested by the patient to facilitate oral hygiene procedures or to improve esthetics
Patients in need of a graft of approximately 15 x 10 x 20 mm in dimension

Exclusion Criteria

Subjects with potential medical complications such as evidence of clinically significant (as described by investigators) renal, hepatic, cardiac, endocrine, hematologic, autoimmune, or any systemic disease which may complication execution of the protocol and/or interpretation of results
Current radiation therapy or history of radiation therapy treatment to the intraoral donor biopsy site or recipient site for graft placement
Documented history of syphilis, HIV, Hepatitis B or C virus
Pregnant women or women planning to become pregnant or unwilling to abstain or use double barrier contraceptives during the course of the study
Smoking or use of tobacco products within 6 months prior to screening
History of either alcohol or drug abuse
Subjects taking medications that can result in gingival enlargement/overgrowth (Cyclosporine, Dilantin, calcium channel blockers)
Current use of intravenous bisphosphonate or current oral bisphosphate use or a history of bisphosphonate use for over 5 years

Arm && Interventions

Group	Intervention	Description
Palatal Oral Mucosa (POM) Graft	POM (Palatal oral mucosa)	Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
Ex vivo Produced Oral Mucosa Equivalent	EVPOME (autogenous ex vivo produced oral mucosa equivalent)	Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area

Primary Outcome Measures

Name	Time	Method
Clinical Increase in Zone (Width) of Keratinized Mucosa at Grafted Site	2 and 4 weeks post surgical graft	The keratinized mucosa (KM) width will be measured by determining the distance from the crest of the edentulous ridge to the mucogingival line to the nearest millimeter with a Castroviejo caliper. The keratinized mucosa width of study subjects was measured prior to graft placement and then after two weeks, and after 4 weeks. The data provided shows the difference in keratinized mucosa width between the pre surgery measure and the post surgery measure. More mucosa width (positive numbers in mm) is an improvement, negative numbers (a decrease) would be less good.

Secondary Outcome Measures

Name	Time	Method
Graft Contracture	2, 4, 8 and 24 weeks after surgery	Graft measurements collected at each time point post graft surgery, 2 weeks, 4 weeks, 8 weeks and 24 weeks. Measurements collected, Horizontal Coronal (mm), Horizontal Apical (mm), Vertical between coronal and apical (mm), were used to determine the area of the graft as a trapezoid like shape. The area of the graft at each time point was compared to the area of the graft at the time of implantation (graft surgery) to determine the % of graft contracture from implantation thru each follow-up time point. Less graft contracture is considered a better outcome.